|
US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
EP0318554B2
(en)
|
1987-05-21 |
2005-01-12 |
Micromet AG |
Targeted multifunctional proteins
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
DE69133566T2
(de)
|
1990-01-12 |
2007-12-06 |
Amgen Fremont Inc. |
Bildung von xenogenen Antikörpern
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
WO1992003918A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6770274B1
(en)
|
1990-09-14 |
2004-08-03 |
The General Hospital Corporation |
Viral mutant HSV mediated destruction of neoplastic cells
|
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
|
JP3266311B2
(ja)
|
1991-05-02 |
2002-03-18 |
生化学工業株式会社 |
新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
|
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
|
US5858657A
(en)
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Technology Ltd. |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
|
US5855885A
(en)
|
1993-01-22 |
1999-01-05 |
Smith; Rodger |
Isolation and production of catalytic antibodies using phage technology
|
|
US5728379A
(en)
|
1994-06-23 |
1998-03-17 |
Georgetown University |
Tumor- or cell-specific herpes simplex virus replication
|
|
US6699468B1
(en)
|
1994-06-23 |
2004-03-02 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
|
US5585096A
(en)
|
1994-06-23 |
1996-12-17 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
|
US5702892A
(en)
|
1995-05-09 |
1997-12-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Phage-display of immunoglobulin heavy chain libraries
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
|
US5824318A
(en)
|
1996-07-24 |
1998-10-20 |
American Cyanamid Company |
Avirulent herpetic viruses useful as tumoricidal agents and vaccines
|
|
CA2722378C
(en)
|
1996-12-03 |
2015-02-03 |
Amgen Fremont Inc. |
Human antibodies that bind tnf.alpha.
|
|
US6057098A
(en)
|
1997-04-04 |
2000-05-02 |
Biosite Diagnostics, Inc. |
Polyvalent display libraries
|
|
US6379674B1
(en)
|
1997-08-12 |
2002-04-30 |
Georgetown University |
Use of herpes vectors for tumor therapy
|
|
EP1053752A1
(en)
|
1998-02-10 |
2000-11-22 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Preparations with controlled release
|
|
DE69909459T2
(de)
|
1998-04-21 |
2004-05-27 |
Micromet Ag |
Cd19xcd3 spezifische polypeptide und deren verwendung
|
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
|
WO2000040734A1
(en)
|
1998-12-31 |
2000-07-13 |
Arch Development Corporation |
Recombinant herpes simplex virus useful for treating neoplastic disease
|
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
|
AU2905199A
(en)
|
1999-03-15 |
2000-10-04 |
Trustees Of The University Of Pennsylvania, The |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
US6764675B1
(en)
|
1999-06-08 |
2004-07-20 |
The Uab Research Foundation |
Herpes simplex virus expressing foreign genes and method for treating cancers therewith
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
ES2254359T3
(es)
|
2000-01-21 |
2006-06-16 |
Biovex Limited |
Cepa viral para el tratamiento oncolitico de canceres.
|
|
WO2001058479A1
(en)
|
2000-02-08 |
2001-08-16 |
The Penn State Research Foundation |
Immunotherapy using interleukin 13 receptor subunit alpha 2
|
|
EP1381280B1
(en)
|
2001-03-27 |
2011-05-11 |
Catherex, Inc. |
Viral vectors and their use in therapeutic methods
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
DK1451322T3
(da)
|
2001-11-05 |
2010-02-01 |
Zymogenetics Inc |
Il-21-antagonister
|
|
WO2003048731A2
(en)
|
2001-12-03 |
2003-06-12 |
Abgenix, Inc. |
Antibody categorization based on binding characteristics
|
|
US7494804B2
(en)
|
2002-01-18 |
2009-02-24 |
Zymogenetics, Inc. |
Polynucleotide encoding cytokine receptor zcytor17 multimer
|
|
US7736652B2
(en)
|
2002-03-21 |
2010-06-15 |
The Regents Of The University Of California |
Antibody fusion proteins: effective adjuvants of protein vaccination
|
|
PT1531850E
(pt)
|
2002-06-07 |
2012-05-07 |
Zymogenetics Inc |
Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
|
|
DE60331455D1
(de)
|
2002-10-04 |
2010-04-08 |
Microchips Inc |
Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
|
|
CN1513993A
(zh)
|
2002-12-31 |
2004-07-21 |
北京博泰迪生物工程科技开发有限公司 |
中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
|
|
RU2005141512A
(ru)
|
2003-05-31 |
2007-07-20 |
Микромет Аг (De) |
Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
|
|
WO2005030196A2
(en)
|
2003-09-25 |
2005-04-07 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using il-21
|
|
KR20120125634A
(ko)
|
2003-10-16 |
2012-11-16 |
마이크로메트 에이지 |
다중특이적 탈면역화된 ｃｄ3-바인더
|
|
BRPI0511782B8
(pt)
|
2004-06-03 |
2021-05-25 |
Novimmune Sa |
anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
EP1861399B1
(en)
|
2005-03-14 |
2011-12-14 |
Merck Sharp & Dohme Corp. |
Cgrp receptor antagonists
|
|
WO2006111524A2
(en)
|
2005-04-18 |
2006-10-26 |
Novo Nordisk A/S |
Il-21 variants
|
|
EP1896582A4
(en)
|
2005-05-09 |
2009-04-08 |
Ono Pharmaceutical Co |
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
|
|
PL1963369T3
(pl)
|
2005-11-28 |
2013-10-31 |
Zymogenetics Inc |
Antagoniści IL-21
|
|
US7592427B2
(en)
|
2005-11-28 |
2009-09-22 |
Zymogenetics, Inc. |
Antibodies to IL-21 receptor
|
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
|
BRPI0709787A2
(pt)
|
2006-05-08 |
2011-03-29 |
Philogen Spa |
citocinas com anticorpos alvejados para terapia
|
|
CN101553501A
(zh)
|
2006-10-26 |
2009-10-07 |
诺沃-诺迪斯克有限公司 |
Il-21变种
|
|
CA2671665A1
(en)
|
2006-12-21 |
2008-06-26 |
Novo-Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
|
CN101230335B
(zh)
|
2007-01-22 |
2010-08-11 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
|
CN101230334B
(zh)
|
2007-01-22 |
2011-06-01 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
|
SG182234A1
(en)
|
2007-04-03 |
2012-07-30 |
Amgen Res Munich Gmbh |
Cross-species-specific cd3-epsilonbinding domain
|
|
PT2520590T
(pt)
|
2007-04-03 |
2018-11-14 |
Amgen Res Munich Gmbh |
Domínio de ligação específico de espécies cruzadas
|
|
RU2422134C1
(ru)
|
2007-04-19 |
2011-06-27 |
Донг-А Фармасьютикал. Ко., Лтд |
Композиция биоразлагающихся микросфер, пригодная для контролируемого высвобождения контролирующего уровень глюкозы пептида, и ее состав
|
|
EP2426146B1
(en)
|
2007-12-07 |
2016-02-17 |
ZymoGenetics, Inc. |
Anti-human IL-21 monoclonal antibodies
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
CN102089325A
(zh)
|
2008-04-17 |
2011-06-08 |
埃博灵克斯股份有限公司 |
能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
|
|
AU2009299792B2
(en)
|
2008-10-01 |
2015-07-16 |
Amgen Research (Munich) Gmbh |
Cross-species-specific PSMAxCD3 bispecific single chain antibody
|
|
US20120107267A1
(en)
*
|
2009-03-11 |
2012-05-03 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
CN102369215B
(zh)
|
2009-04-02 |
2015-01-21 |
罗切格利卡特公司 |
包含全长抗体和单链Fab片段的多特异性抗体
|
|
KR20120027055A
(ko)
|
2009-06-26 |
2012-03-20 |
리제네론 파라마큐티칼스 인코포레이티드 |
천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
|
|
KR20120053042A
(ko)
|
2009-08-17 |
2012-05-24 |
로슈 글리카트 아게 |
표적화된 면역접합체
|
|
CN102741280B
(zh)
|
2009-10-30 |
2015-12-02 |
诺维信生物制药丹麦公司 |
白蛋白变体
|
|
CA3253628A1
(en)
|
2010-03-05 |
2025-11-29 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
US20130225496A1
(en)
|
2010-11-01 |
2013-08-29 |
Novozymes Biopharma Dk A/S |
Albumin Variants
|
|
US20120258073A1
(en)
|
2011-02-10 |
2012-10-11 |
Christian Gerdes |
Immunotherapy
|
|
EP2686682A4
(en)
|
2011-03-11 |
2015-03-11 |
Amgen Inc |
METHOD FOR CORRELATED MUTATION ANALYSIS TO IMPROVE THERAPEUTIC ANTIBODIES
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
CN104011072B
(zh)
|
2011-05-05 |
2018-10-12 |
阿尔布梅迪克斯医疗有限公司 |
白蛋白变体
|
|
WO2012178137A1
(en)
|
2011-06-24 |
2012-12-27 |
Gillies Stephen D |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
US20130028882A1
(en)
|
2011-07-07 |
2013-01-31 |
Humanitas Technology, LLC |
Antiviral compositions and methods of their use
|
|
PL2753355T3
(pl)
|
2011-09-08 |
2019-04-30 |
Benevir Biopharm Inc |
Onkolityczny wirus opryszczki pospolitej i jego zastosowania lecznicze
|
|
ES3033729T3
(en)
|
2011-10-28 |
2025-08-07 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US20140315817A1
(en)
|
2011-11-18 |
2014-10-23 |
Eleven Biotherapeutics, Inc. |
Variant serum albumin with improved half-life and other properties
|
|
US20150030562A1
(en)
|
2011-12-23 |
2015-01-29 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Methods of treating or preventing viral diseases by blocking interleukin-21
|
|
US9447160B2
(en)
|
2012-01-19 |
2016-09-20 |
University Of Miami |
Compositions, methods and kits for treatment of cancer and autoimmune diseases
|
|
WO2013135896A1
(en)
|
2012-03-16 |
2013-09-19 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
|
CA3004695C
(en)
|
2012-04-30 |
2020-08-04 |
Biocon Limited |
Targeted/immunomodulatory fusion proteins and methods for making same
|
|
EP2847219A1
(en)
|
2012-05-07 |
2015-03-18 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
|
WO2013169693A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
AR092044A1
(es)
|
2012-08-07 |
2015-03-18 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
US20140128326A1
(en)
|
2012-11-08 |
2014-05-08 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
|
WO2014139468A1
(en)
|
2013-03-15 |
2014-09-18 |
Admark Healthcare, Llc |
Fusion protein molecules and method of use
|
|
ES2845609T3
(es)
|
2013-05-02 |
2021-07-27 |
Anaptysbio Inc |
Anticuerpos dirigidos contra muerte programada-1 (PD-1)
|
|
WO2015000585A1
(en)
*
|
2013-07-02 |
2015-01-08 |
Walter Sebald |
Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
|
|
KR102361237B1
(ko)
|
2013-07-11 |
2022-02-09 |
더 스크립스 리서치 인스티튜트 |
코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
|
|
HUE046249T2
(hu)
|
2013-12-12 |
2020-02-28 |
Shanghai hengrui pharmaceutical co ltd |
PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
CA2935665A1
(en)
|
2014-02-06 |
2015-08-13 |
F. Hoffmann-La Roche Ag |
Interleukine 10 immunoconjugates
|
|
AU2015221181B2
(en)
|
2014-02-19 |
2020-08-20 |
Merck Patent Gmbh |
Cancer-targeted IL-12 immunotherapy
|
|
LT3128997T
(lt)
|
2014-04-08 |
2020-10-12 |
Boston Pharmaceuticals Inc. |
Surišančios molekulės, specifinės il-21, ir jų panaudojimas
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
WO2016100375A2
(en)
|
2014-12-15 |
2016-06-23 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
|
CN107249633A
(zh)
|
2014-12-19 |
2017-10-13 |
迈博太科公司 |
用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法
|
|
KR20160113452A
(ko)
|
2015-03-20 |
2016-09-29 |
(주)엘지하우시스 |
진공 단열재용 심재 및 진공단열재
|
|
ES2898958T3
(es)
|
2015-07-30 |
2022-03-09 |
Macrogenics Inc |
Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究（慕尼黑）公司 |
Dll3及cd3抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
EP3328377A4
(en)
|
2015-07-31 |
2019-03-13 |
Tarveda Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
|
|
US11008391B2
(en)
|
2015-08-11 |
2021-05-18 |
WuXi Biologics Ireland Limited |
Anti-PD-1 antibodies
|
|
HK1257840A1
(zh)
|
2015-09-01 |
2019-11-01 |
Agenus Inc. |
抗-pd-1抗体及其使用方法
|
|
UA123826C2
(uk)
|
2015-10-02 |
2021-06-09 |
Ф. Хоффманн-Ля Рош Аг |
Антитіла до pd1 та способи їх застосування
|
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
PT3394103T
(pt)
*
|
2015-12-22 |
2023-09-04 |
Regeneron Pharma |
Combinação de anticorpos anti-pd-1 e anticorpos biespecíj'icos anti-cd20/anti-cd3 para tratar cancro
|
|
CN109415703B
(zh)
|
2016-01-08 |
2024-08-30 |
雷普利穆内有限公司 |
经修饰的溶瘤病毒
|
|
WO2017123643A1
(en)
|
2016-01-11 |
2017-07-20 |
Flagship Pioneering, Inc. |
Methods and compositions for modulating thymic function
|
|
SG11201805770UA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
UY37105A
(es)
|
2016-02-03 |
2017-09-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
|
|
CA3013554A1
(en)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Targeted therapeutic agents and uses thereof
|
|
US11053293B2
(en)
|
2016-02-05 |
2021-07-06 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
US11186641B2
(en)
|
2016-03-17 |
2021-11-30 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
US20190183931A1
(en)
|
2016-04-01 |
2019-06-20 |
Amgen Inc. |
Chimeric receptors to flt3 and methods of use thereof
|
|
WO2017181420A1
(en)
|
2016-04-22 |
2017-10-26 |
Immuno Vir Co., Limited |
CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY
|
|
RU2021127872A
(ru)
|
2016-06-30 |
2021-11-09 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
|
RU2656181C1
(ru)
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
|
US12162919B2
(en)
|
2016-08-01 |
2024-12-10 |
Virogin Biotech Canada Ltd |
Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
|
|
KR101928981B1
(ko)
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
|
|
EA201990672A1
(ru)
|
2016-09-14 |
2019-08-30 |
Бэйцзин Ханми Фарм. Ко., Лтд. |
Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
|
|
DK3515938T3
(da)
|
2016-09-21 |
2025-04-07 |
Cstone Pharmaceuticals |
Monoklonale antistoffer mod programmeret død 1 (pd-1)
|
|
WO2018057943A1
(en)
|
2016-09-23 |
2018-03-29 |
Oncosec Medical Incorporated |
Modulating responses to checkpoint inhibitor therapy
|
|
SI3535298T1
(sl)
|
2016-11-02 |
2022-01-31 |
Jounce Therapeutics, Inc. |
Protitelesa proti pd-1 in njihove uporabe
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
AU2018298060B2
(en)
|
2017-07-03 |
2021-02-25 |
Torque Therapeutics, Inc. |
Immunostimulatory fusion molecules and uses thereof
|
|
US20210260163A1
(en)
|
2018-03-09 |
2021-08-26 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
CA3095310A1
(en)
|
2018-03-28 |
2019-10-03 |
Orionis Biosciences, Inc. |
Bi-functional proteins and construction thereof
|
|
KR20210018797A
(ko)
|
2018-04-10 |
2021-02-18 |
암젠 인크 |
Dll3에 대한 키메라 수용체 및 이의 사용 방법
|
|
KR20210021486A
(ko)
|
2018-06-18 |
2021-02-26 |
안위타 바이오사이언시스, 인코포레이티드 |
사이토카인 융합 단백질 및 이의 용도
|
|
CN113164558A
(zh)
|
2018-09-28 |
2021-07-23 |
皮埃尔法布雷医药公司 |
用于治疗癌症的新型免疫细胞因子
|
|
WO2020127369A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional molecule directed against human pd-1
|